SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study | Zendy

Min Xu | Zendy; Jie Zheng | Zendy; Tianzhichao Hou | Zendy; Hong Lin | Zendy; Tiange Wang | Zendy; Shuangyuan Wang | Zendy; Jieli Lu | Zendy; Zhiyun Zhao | Zendy; Mian Li | Zendy; Yu Xu | Zendy; Guang Ning | Zendy; Yufang Bi | Zendy; Weiqing Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study

Author(s) -

Min Xu,

Jie Zheng,

Tianzhichao Hou,

Hong Lin,

Tiange Wang,

Shuangyuan Wang,

Jieli Lu,

Zhiyun Zhao,

Mian Li,

Yu Xu,

Guang Ning,

Yufang Bi,

Weiqing Wang

Publication year - 2022

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc22-0323

Subject(s) - mendelian randomization , medicine , coronary artery disease , type 2 diabetes , choline , odds ratio , diabetes mellitus , endocrinology , gastroenterology , bioinformatics , genetics , biology , gene , genotype , genetic variants

To investigate the causal role of choline metabolites mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in coronary artery disease (CAD) and type 2 diabetes (T2D) using Mendelian randomization (MR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research